Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880160 | 0.88 | OPRK1 (0.53) | P2RY12CYP3A4CYP2C9OPRK1MAPT | |
| SCHEMBL4881192 | 0.85 | P2RY12 (0.48) | P2RY12CYP3A4CYP2C9OPRK1MAPT | |
| SCHEMBL3221673 | 0.83 | P2RY12 (0.69) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL5592386 | 0.82 | P2RY12 (0.63) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL4876337 | 0.80 | P2RY12 (0.77) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4100121 | 0.79 | P2RY12 (0.61) | P2RY12 | |
| SCHEMBL5014112 | 0.78 | P2RY12 (0.63) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL4874256 | 0.78 | P2RY12 (0.77) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL5014008 | 0.77 | P2RY12 (0.62) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL4878784 | 0.77 | P2RY12 (0.45) | P2RY12CYP3A4CYP2C9OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| CN-101263133-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 140/4885CYP2C9 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.